In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report), with a price target of $76.00. The company’s shares closed last Monday at $72.37.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.8% and a 58.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, BioMarin Pharmaceutical, and Fusion Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co with a $102.86 average price target.
Based on Biohaven Pharmaceutical Holding Co’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $35.11 million and GAAP net loss of $218 million. In comparison, last year the company had a GAAP net loss of $149 million.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.